13.04.2016 08:20:19

CellaVision AB: CellaVision's 2015 Annual Report now available

2016-04-13
 
Today, Cellavision announced that the company's Annual Report for 2015 is available as PDF at www.cellavision.com, and can be read via the link below.
 
To request a printed version, please visit the investor pages at CellaVision's website.
 
For more information, please contact:
Zlatko Rihter, CEO, CellaVision AB
 
Phone: +46 733 62 11 06 | E-mail: zlatko.rihter@cellavision.com
 

About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The analyses often constitute important reference data for fast and correct diagnosis of illnesses such as viral and bacterial infections and cancers. CellaVision's products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. In 2015 sales were SEK 239 million. Sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's head office is in Lund, Sweden and the company has subsidiaries in the USA, Canada and Japan. The share is listed on the Nasdaq Stockholm, Small Cap list. Read more at www.cellavision.com
 



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CellaVision AB via Globenewswire

HUG#2002962

Analysen zu Cellavision ABmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Cellavision AB 19,36 1,57% Cellavision AB